Molecular mechanism of the additive effects of leukotriene modifier in asthmatic patients receiving steroid therapy

Allergology International

Volumn 58, Issue 1, 2009, Pages 89-96

  Matsunaga, Kazuto ^a   Yanagisawa, Satoru ^a   Ichikawa, Tomohiro ^a   Akamatsu, Keiichiro ^a   Koarai, Akira ^a   Hirano, Tsunahiko ^a   Sugiura, Hisatoshi ^a   Minakata, Yoshiaki ^a   Ichinose, Masakazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Airflow limitation; Airway hyperresponsiveness; Airway lability; Exhaled breath condensate; RANTES

Indexed keywords

CORTICOSTEROID; FLUTICASONE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 8; LEUKOTRIENE; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONTELUKAST; PRANLUKAST; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

EID: 65449131569     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-OA-0014     Document Type: Article

References (35)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl 5):S147-34.
2. Busse WW, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127: 1312-26.
3. Reiss TF, Chervinsky PS, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998; 158:1213-20.
4. Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, Ghannam AF. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002;110:847-54.
5. Nayak AS, Phillip G, Lu S, Malice M-P, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88: 592-600.
6. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58(Suppl 1):1-94.
7. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995;152:45-52.
8. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 2000;162:578-85.
9. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211-6.
10. Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006;61:737-42.
11. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003;327:891-6.
12. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167:1232-8.
13. Barnes N, Laviolette M, Allen D et al. Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control. Respir Med 2007;101: 1652-8.
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987;136:225-44.
15. Hovarth I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26:523-48.
16. Matsunaga K, Yanagisawa S, Ichikawa T et al. Airway cytokine expression measured by means of protein array in exhaled breath condensate: Correlation with physiologic properties in asthmatic patients. J Allergy Clin Immunol 2006;118:84-90.
17. Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respir Crit Care Med 1995; 151:1320-5.
18. Matsunaga K, Kanda M, Hayata A et al. Peak expiratory flow variability adjusted by forced expiratory volume in one second is a good index for airway responsiveness in asthmatics. Intern Med 2008; 47:1107-12.
19. National Heart, Lung, and Blood Institute/World Health Organization. Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention, Updated 2006. Bethesda: NIH Publication, 2006.
20. Braunstahl GJ, Kleinjan A, Overbeek SE, McEuen AR, Walls AF. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:2051-7.
21. Corren J, Adinoff AD, Irvin CG et al. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992;89:611-8.
22. Lee E, Robertson T, Smith J et al. Leukotriene receptor and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000; 161:1881-6.
23. Kawano T, Matsuse H, Kondo H et al. Cysteinyl leukotrienes induce nuclear factor kB activation and RANTES production in a murine model of asthma. J Allergy Clin Immunol 2003;112:369-74.
24. Rajakulasingam K, Hamid Q, O'Brien F et al. RANTES in human allergen-induced rhinitis. Am J Respir Crit Care Med 1997; 155:696-703.
25. Ueda T, Takeno S, Furukido K et al. Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis. Ann Otol Rhinol Laryngol 2003;112: 955-61.
26. Gaga M, Lambrou P, Papageorgiou N et al. Eosinophils are a feature of upper and lower airway pathology in nonatopic asthma, irrespective of the presence of rhinitis. Clin Exp Allegy 2000;30:663-9.
27. Higashi N, Taniguchi M, Mita H, Ishii T, Akiyama K. Nasal blockage and urinary leukotriene E4 concentration in patients with seasonal allergic rhinitis. Allergy 2003;58: 476-80.
28. Miadonna A, Tedeschi A, Leggieri E et al. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987;136:357-62.
29. Pavord ID, Ward R, Woltmann G et al. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999; 160:1905-9.
30. Wenzel SE, Larsen GL, Johnston K et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142:112-9.
31. Jeffery PK, Haahtela T. Allergic rhinitis and asthma: inflammation in a one-airway condition. BMC Pulm Med 2006;6(Suppl 1):S5.
32. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54:825-57.
33. Gavreau GM, Watson RM, O'Byrne PM et al. Kinetics of allergen-induced eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med 1999; 160:640-7.
34. Castro M, Bloch SR, Jenkerson MV et al. Asthma exacerbations after glucocorticoid withdrawal reflect T cell recruitment to the airway. Am J Respir Crit Care Med 2004; 169:842-9.
35. Gonzalo JA, Lloyd C, Wen D et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway responsiveness. J Exp Med 1998; 188:157-67.